PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols
PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols
复制标题
DOI：
10.1007/s00345-010-0623-6
复制
发表时间：
2011-10-01
影响因子：
3.4
通讯作者：
Ornstein, David K.
中科院分区：
文献类型：
--
作者：
Liss, Michael A.;Santos, Rosanne;Ornstein, David K.
PCA3是一种非编码的mRNA分子，在前列腺癌中过度表达。这项研究的目的是评估PCA3分子尿测试评分在预测不良病理特征和插管标本收集方面的实用性。临床局限性前列腺癌患者计划接受机器人前列腺切除术，按照标准的同意程序进行研究。研究方案包括提供四个尿样。收集直肠指检(DRE)术前(V1)、无直肠指诊(DRE)的导尿管(V2)、术后10d和术后6周(V3、V4)的尿样进行分析。这四个尿样进行了靶捕获、转录介导的扩增和杂交，以定量PCA3和PSA mRNA。PCA3评分以PCA3/PSA的比值计算，VI、V2、V3、V4的信息率分别为91%、85%、0%和2%。与病理分期、Gleason评分及Gt；6无明显相关性。V1评分越高，神经侵袭风险越高(P=0.0479)。PCA3评分可从排尿后和导尿管尿中获得。PCA3试验似乎不能预测不良的病理特征，但可能与神经侵袭有关。PCA3评分预测临床结果的能力仍有待确定。
PCA3 is a non-coding mRNA molecule that is overexpressed in prostate cancer. The purpose of this study is to evaluate the utility of the PCA3 molecular urine test scores to predict adverse pathologic features and catheterized specimen collection.Hundred men with clinically localized prostate cancer scheduled to undergo robotic prostatectomy were enrolled in the study following a standard consent process. The study protocol consisted of providing four urine samples. Voided urine obtained following digital rectal examination (DRE) pre-operatively (Vl), catheterized urine without DRE (V2), and l0-day and 6-week postoperative voided (V3 and V4) urine samples were collected and analyzed. These four urine specimens underwent target capture, transcription-mediated amplification, and hybridization in order to quantify both PCA3 and PSA mRNA. The PCA3 score was calculated as the ratio of PCA3 to PSA.Informative rates (sufficient mRNA for analysis) for VI, V2, V3 and V4 were 91, 85, 0 and 2%, respectively. There was no significant associations with pathological stage, Gleason score > 6. Higher PCA3 scores at V1 correlated with increased risk for perineural invasion (P = 0.0479).Informative PCA3 scores can be obtained from post-DRE voided urine as well as catheterized urine without a DRE. The PCA3 test does not seem to predict adverse pathologic features, though, may have an association with perineural invasion. The ability of PCA3 score to predict clinical outcome remains to be determined.